Heather Fairhead News Today

Start-ups and scientists are in a race against time to develop new therapies based on phages, tiny bacteria-destroying virus that have the potential to create an alternative to antibiotics.

Phico Therapeutics Ltd today announced that it has established a Science Advisory Board (SAB) to provide strategic scientific guidance to the Company.

Phico Therapeutics raises £7m to advance next-gen antibiotic candidate 11th May 2021 Cambridge, UK-based biotech company Phico Therapeutics has announced new investments of £7m, led by the UK’s most active growth capital investor BGF. The new investments closely follow the recent announcement that Phico has been awarded a grant of up to $18.2m (£13.2m) to support the development of its lead product SASPject PT3.9 from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (C...

Phico Therapeutics gains £13.1m grant to advance antibacterial therapy 19th April 2021 Cambridge, UK-based Phico Therapeutics has been awarded a grant of up to £13.2m ($18.2m) to take its lead antibacterial therapy through Phase I clinical trials. The grant comes from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership seeking to accelerate antibacterial research against the growing threat of drug-resistant bacteria. The funds will ...